Serum cystatin C Is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations

Journal of Korean Medical Science

Volumn 28, Issue 1, 2013, Pages 48-54

  Chung, Jae Yong ^a   Jin, Sung Joon ^b   Yoon, Ji Hyun ^b   Song, Young Goo ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Cystatin C; NONMEM; Pharmacokinetics; TDM; Vancomycin

Indexed keywords

ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CREATININE; CYSTATIN C; VANCOMYCIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLOOD; BODY WEIGHT; COMPUTER PROGRAM; DEMOGRAPHY; FEMALE; HUMAN; MALE; MIDDLE AGED; NONMEM; PHARMACOKINETICS; SEX DIFFERENCE; STATISTICAL MODEL; TDM; VERY ELDERLY;

CYSTATIN C; NONMEM; PHARMACOKINETICS; TDM; VANCOMYCIN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; BODY WEIGHT; CREATININE; CYSTATIN C; DEMOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; SEX FACTORS; SOFTWARE; VANCOMYCIN; YOUNG ADULT;

EID: 84874774161     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.1.48     Document Type: Article

References (27)

1. Appelbaum PC. Microbiology of antibiotic resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45 Suppl 3: S165-70.
2. Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 2003; 26: 876-9.
3. MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998; 20: 473-7.
4. Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A, Alberino F, Gatta A. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994; 154: 201-5.
5. Ross EA, Wilkinson A, Hawkins RA, Danovitch GM. The plasma creatinine concentration is not an accurate reflection of the glomerular filtration rate in stable renal transplant patients receiving cyclosporine. Am J Kidney Dis 1987; 10: 113-7.
6. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-6.
7. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem 2005; 38: 1-8.
8. Hermida J, Tutor JC. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther Drug Monit 2006; 28: 326-31.
9. Okamoto G, Sakamoto T, Kimura M, Ukishima Y, Sonoda A, Mori N, Kato Y, Maeda T, Kagawa Y. Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin Biochem 2007; 40: 485-90.
10. Suzuki A, Imanishi Y, Nakano S, Niwa T, Ohmori T, Shirai K, Yoshida S,Furuta N, Takemura M, Ito H, et al. Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients. J Pharm Pharmacol 2010; 62: 901-7.
11. Jin SJ, Bae SC, Kim HW, Kim HK, Na EJ, Ahn BS, Choi JY, Kim CO, Kim JM, Song YG. Evaluation of the effect of initial dose of vancomycin using serum cystatin C as a marker in elderly patients. Infect Chemother 2009; 41: 224-9.
12. Tanaka A, Aiba T, Otsuka T, Suemaru K, Nishimiya T, Inoue T, Murase M, Kurosaki Y, Araki H. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother 2010; 54: 778-82.
13. Jonsson EN, Karlsson MO. Xpose--an S-PLUS based population pharmacokinetic/ pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
14. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-57.
15. Parke J, Holford NHG, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999; 59: 19-29.
16. Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm 1994; 22: 165-77.
17. Nielsen EI, Sandstrom M, Honore PH, Ewald U, Friberg LE. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet 2009; 48: 253-63.
18. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003; 18: 2024-31.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
20. Martin JH, Norris R, Barras M, Roberts J, Morris R, Doogue M, Jones GR. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Clin Biochem Rev 2010; 31: 21-4.
21. Buelga DS, del Mar Fernandez de Gatta M, Herrera EV, Dominguez-Gil A, Garcia MJ. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother 2005; 49: 4934-41.
22. Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 2006; 31: 447-54.
23. Sanchez JL, Dominguez AR, Lane JR, Anderson PO, Capparelli EV, Cornejo-Bravo JM. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int J Clin Pharmacol Ther 2010; 48: 525-33.
24. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009; 63: 1050-7.
25. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 558-69.
26. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994; 16: 513-8.
27. Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, Hori R. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit 1998; 20: 139-48.